Reports

To assist health care providers, policy-makers, and consumers in making well-informed decisions about the prescribing and use of proton pump inhibitors, our completed research and resulting recommendations are available in a series of Optimal Therapy Reports that provide:

• evidence-based clinical statements and cost-effectiveness statements
• a clear picture of current practice and current utilization in Canada
• an analysis of the quantity of proton pump inhibitor agents prescribed, including market share and cost information
• an outline of gaps between current prescribing and use.

Summary Reports

• Project in Brief (one-page synopsis of clinical reports) 
• Executive Summary (three-page synopsis of clinical reports)
• Overview Report (25 page synopsis of clinical reports)

Final Reports

• Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report. Optimal Therapy Report - COMPUS 2007;1(2).
• Canadian Agency for Drugs and Technologies in Health. Economic models and conclusions for the treatment of dyspepsia; and gastroesophageal reflux disease - related heartburn and the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal complications. Optimal Therapy Report - COMPUS 2007;1(3).
• Canadian Agency for Drugs and Technologies in Health. Interventions for appropriate prescribing of proton pump inhibitors: a literature review. Optimal Therapy Report - COMPUS 2007;1(4).
• Canadian Agency for Drugs and Technologies in Health. Current practice analysis report for the prescribing and use of proton pump inhibitors. Optimal Therapy Report - COMPUS 2007;1(5).
• Canadian Agency for Drugs and Technologies in Health. Gap analysis report for the prescribing and use of proton pump inhibitors. Optimal Therapy Report - COMPUS 2007;1(6).
• Canadian Agency for Drugs and Technologies in Health. Selection of interventions report: PPI project. Optimal Therapy Report - COMPUS 2007;1(7).